

Ronan Roussel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8278833/ronan-roussel-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

139
papers

4,695
citations

29
h-index

66
g-index

149
ext. papers

6,006
ext. citations

8.1
avg, IF

5.26
L-index

#	Paper	IF	Citations
139	Epigenetic changes associated with hyperglycaemia exposure in the longitudinal D.E.S.I.R. cohort.. <i>Diabetes and Metabolism</i> , 2022 , 101347	5.4	
138	Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 71	8.7	0
137	Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. <i>Diabetes and Metabolism</i> , 2021 , 48, 101306	5.4	
136	Association Between the Insertion/Deletion Polymorphism and Risk of Lower-Limb Amputation in Patients With Long-Standing Type 1 Diabetes. <i>Diabetes Care</i> , 2021 ,	14.6	1
135	Stay-at-Home Orders During the COVID-19 Pandemic, an Opportunity to Improve Glucose Control Through Behavioral Changes in Type 1 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 839-843	14.6	16
134	Une vision de l'organisation moderne d'un service hospitalier de diabétologie. <i>Medecine Des Maladies Metaboliques</i> , 2021 , 15, 585-590	0.1	0
133	I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 1377-1384	14.6	3
132	Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. <i>Diabetes Care</i> , 2021 , 44, 1368-1376	14.6	11
131	SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis. <i>Cardiovascular Diabetology</i> , 2021 , 20, 107	8.7	3
130	Diabetes Increases Severe COVID-19 Outcomes Primarily in Younger Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e3364-e3368	5.6	3
129	Is the Consensual Threshold for Defining High Glucose Variability Implementable in Clinical Practice?. <i>Diabetes Care</i> , 2021 , 44, 1722-1725	14.6	1
128	Association of diabetes and outcomes in patients with COVID-19: Propensity score-matched analyses from a French retrospective cohort. <i>Diabetes and Metabolism</i> , 2021 , 47, 101222	5.4	7
127	Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. <i>Diabetes and Metabolism</i> , 2021 , 47, 101216	5.4	36
126	Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study. <i>Diabetologia</i> , 2021 , 64, 668-680	10.3	5
125	Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. <i>Diabetologia</i> , 2021 , 64, 778-794	10.3	61
124	Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1162-1172	6.7	19
123	COVID-19 symptoms masking inaugural ketoacidosis of type 1 diabetes. <i>Diabetes and Metabolism</i> , 2021 , 47, 101162	5.4	16

122	The COVID-19 lockdown as an opportunity to change lifestyle and body weight in people with overweight/obesity and diabetes: Results from the national French COVIDIAB cohort. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2605-2611	4.5	3
121	Exposure to persistent organic pollutants and the risk of type 2 diabetes: a case-cohort study. <i>Diabetes and Metabolism</i> , 2021 , 47, 101234	5.4	3
120	Reliability and Safety of Bedside Blind Bone Biopsy Performed by a Diabetologist for the Diagnosis and Treatment of Diabetic Foot Osteomyelitis. <i>Diabetes Care</i> , 2021 , 44, 2480-2486	14.6	0
119	History of bariatric surgery and COVID 19 outcomes in patients with type 2 diabetes: results from the CORONADO study. <i>Obesity</i> , 2021 ,	8	1
118	Identification of Key Regions Mediating Human Melatonin Type 1 Receptor Functional Selectivity Revealed by Natural Variants. <i>ACS Pharmacology and Translational Science</i> , 2021 , 4, 1614-1627	5.9	2
117	Comparison of a new versus standard removable offloading device in patients with neuropathic diabetic foot ulcers: a French national, multicentre, open-label randomized, controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	1
116	Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. <i>Diabetologia</i> , 2020 , 63, 1500-1515	10.3	442
115	Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI Program. <i>Diabetes Care</i> , 2020 , 43, e43-e44	14.6	7
114	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. <i>Diabetes Care</i> , 2020 , 43, 1695-1703	14.6	65
113	Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020 , 11, 1861-1872	3.6	0
112	Leukocyte Telomere Length, DNA Oxidation, and Risk of Lower-Extremity Amputation in Patients With Long-standing Type 1 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 828-834	14.6	7
111	Relationship between renal capacity to reabsorb glucose and renal status in patients with diabetes. <i>Diabetes and Metabolism</i> , 2020 , 46, 488-495	5.4	1
110	Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2020 , 36, 571-581	2.5	6
109	SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes. <i>Diabetes and Metabolism</i> , 2020 , 46, 203-209	5.4	3
108	Pathogenic variants in actionable MODY genes are associated with type 2 diabetes. <i>Nature Metabolism</i> , 2020 , 2, 1126-1134	14.6	9
107	Adipocyte Reprogramming by the Transcriptional Coregulator GPS2 Impacts Beta Cell Insulin Secretion. <i>Cell Reports</i> , 2020 , 32, 108141	10.6	4
106	Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study. <i>Diabetes Care</i> , 2020 , 43, e174-e177	14.6	26
105	Relationship Between Diabetic Retinopathy Stages and Risk of Major Lower-Extremity Arterial Disease in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 2751-2759	14.6	3

104	Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, Jñi P et al [letter]. <i>Diabetologia</i> , 2020 , 63, 2491-2494	10.3	4
103	Head-to-head comparison of the diagnostic performances of Rubidium-PET and SPECT with CZT camera for the detection of myocardial ischemia in a population of women and overweight individuals. <i>Journal of Nuclear Cardiology</i> , 2020 , 27, 755-768	2.1	6
102	Dairy consumption is associated with lower plasma dihydroceramides in women from the D.E.S.I.R. cohort. <i>Diabetes and Metabolism</i> , 2020 , 46, 144-149	5.4	1
101	Disagreement between capillary blood glucose and flash glucose monitoring sensor can lead to inadequate treatment adjustments during pregnancy. <i>Diabetes and Metabolism</i> , 2020 , 46, 158-163	5.4	6
100	The expression of genes in top obesity-associated loci is enriched in insula and substantia nigra brain regions involved in addiction and reward. <i>International Journal of Obesity</i> , 2020 , 44, 539-543	5.5	16
99	Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analogues. <i>Diabetes/Metabolism Research and Reviews</i> , 2020 , 36, e3329	7.5	5
98	Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	18
97	Plasma Apelin and Risk of Type 2 Diabetes in a Cohort From the Community. <i>Diabetes Care</i> , 2020 , 43, e15-e16	14.6	8
96	Glycosuria amount in response to hyperglycaemia and risk for diabetic kidney disease and related events in Type 1 diabetic patients. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1731-1738	4.3	7
95	New roles for prokineticin 2 in feeding behavior, insulin resistance and type 2 diabetes: Studies in mice and humans. <i>Molecular Metabolism</i> , 2019 , 29, 182-196	8.8	11
94	Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 2290-2297	14.6	10
93	Severe Chronic Kidney Disease Is Associated with a Lower Efficiency of Bariatric Surgery. <i>Obesity Surgery</i> , 2019 , 29, 1514-1520	3.7	11
92	Letter by Potier and Roussel Regarding Article, "Are We Ready to Bell the Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes". <i>Circulation</i> , 2019 , 139, 303-304	16.7	
91	Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study. <i>Diabetes Therapy</i> , 2019 , 10, 617-633	3.6	35
90	Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension. <i>Nature Medicine</i> , 2019 , 25, 1733-1738	50.5	24
89	Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. <i>Diabetologia</i> , 2019 , 62, 939-947	10.3	27
88	Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 781-790	6.7	14
87	Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans. <i>European Journal of Nutrition</i> , 2019 , 58, 315-324	5.2	28

86	No prognostic role of a GWAS-derived genetic risk score in renal outcomes for patients from French cohorts with type 1 and type 2 diabetes. <i>Diabetes and Metabolism</i> , 2019 , 45, 494-497	5.4	1
85	Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM. <i>Diabetes and Metabolism</i> , 2018 , 44, 402-409	5.4	30
84	Agonistes du r�cepteur du GLP-1 : puissance ou transcendance ? Des outils pour contr�ler glyc�mie et pression artfielle. <i>Medecine Des Maladies Metaboliques</i> , 2018 , 12, 31-35	0.1	0
83	Non-severe hypoglycaemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1289-1292	6.7	6
82	Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?. <i>Lancet, The</i> , 2018 , 391, 1680	4.0	1
81	Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 238-244	6.7	42
80	Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis). <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 448-452	6.7	5
79	Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 541-548	6.7	56
78	Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. <i>Cell Metabolism</i> , 2018 , 28, 737-749.e4	24.6	188
77	Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2018 , 17, 110	8.7	19
76	Prognostic Values of Inflammatory and Redox Status Biomarkers on the Risk of Major Lower-Extremity Artery Disease in Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2018 , 41, 2162-2169	14.6	10
75	Bariatric surgery and chronic kidney disease: much hope, but proof is still awaited. <i>International Journal of Obesity</i> , 2018 , 42, 1532-1533	5.5	3
74	Relationship between cardiac microvascular dysfunction measured with ⁸² Rubidium-PET and albuminuria in patients with diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2018 , 17, 11	8.7	21
73	More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. <i>Diabetes Care</i> , 2018 , 41, 2147-2154	14.6	113
72	A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. <i>Diabetes Care</i> , 2018 , 41, 1672-1680	14.6	33
71	Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 943-953	6.7	9
70	Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population. <i>JCI Insight</i> , 2018 , 3,	9.9	20
69	Plasma concentrations of 8-hydroxy-2'-deoxyguanosine and risk of kidney disease and death in individuals with type 1 diabetes. <i>Diabetologia</i> , 2018 , 61, 977-984	10.3	22

68	Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes. <i>Diabetes and Metabolism</i> , 2018 , 44, 15-21	5.4	65
67	Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. <i>Cardiovascular Diabetology</i> , 2018 , 17, 138	8.7	58
66	Le traitement du diabète de type 2 en France est dynamique plutôt qu'instable : analyse des prescriptions de 847 122 patients. <i>Medecine Des Maladies Metaboliques</i> , 2018 , 12, 346-352	0.1	3
65	GPS2 Deficiency Triggers Maladaptive White Adipose Tissue Expansion in Obesity via HIF1A Activation. <i>Cell Reports</i> , 2018 , 24, 2957-2971.e6	10.6	26
64	Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2148-2158	6.7	48
63	Sex hormone levels are not associated with progression of renal disease in male patients with T2DM. <i>Diabetes and Metabolism</i> , 2017 , 43, 140-145	5.4	3
62	T-cadherin gene variants are associated with type 2 diabetes and the Fatty Liver Index in the French population. <i>Diabetes and Metabolism</i> , 2017 , 43, 33-39	5.4	13
61	Predicting severe hypoglycaemia with self-monitoring of blood glucose in type 1 diabetes. <i>Diabetes and Metabolism</i> , 2017 , 43, 392-394	5.4	2
60	Vasopressin and diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2017 , 26, 311-318	3.5	12
59	Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 929-932	3.2	13
58	T-cadherin gene variants are associated with nephropathy in subjects with type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1987-1993	4.3	2
57	Urinary lysophospholipids are increased in diabetic patients with nephropathy. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1103-1108	3.2	14
56	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. <i>Heart</i> , 2017 , 103, 1339-1346	5.1	25
55	Association of Circulating Biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort. <i>Diabetes Care</i> , 2017 , 40, 367-374	14.6	30
54	Urinary Sodium Concentration Is an Independent Predictor of All-Cause and Cardiovascular Mortality in a Type 2 Diabetes Cohort Population. <i>Journal of Diabetes Research</i> , 2017 , 2017, 5327352	3.9	8
53	The vasopressin system: new insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives. <i>Journal of Internal Medicine</i> , 2017 , 282, 310-321	10.8	15
52	De la mémoire du glucose au droit public : quantifier les années d'hyperglycémie. <i>Medecine Des Maladies Metaboliques</i> , 2017 , 11, 278-282	0.1	1
51	Short-term effect of severe hypoglycaemia on glycaemic control in the Diabetes Control and Complications Trial. <i>Diabetes and Metabolism</i> , 2017 , 43, 187-190	5.4	1

50	A Fully Automated Web-Based Program Improves Lifestyle Habits and HbA1c in Patients With Type 2 Diabetes and Abdominal Obesity: Randomized Trial of Patient E-Coaching Nutritional Support (The ANODE Study). <i>Journal of Medical Internet Research</i> , 2017 , 19, e360	7.6	36
49	Association of impaired renal function with venous thrombosis: A genetic risk score approach. <i>Thrombosis Research</i> , 2017 , 158, 102-107	8.2	2
48	Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. <i>Journal of Medical Economics</i> , 2016 , 19, 121-34	2.4	15
47	Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling. <i>Molecular Metabolism</i> , 2016 , 5, 918-925	8.8	13
46	Longitudinal association of antidepressant medication use with metabolic syndrome: Results of a 9-year follow-up of the D.E.S.I.R. cohort study. <i>Psychoneuroendocrinology</i> , 2016 , 74, 34-45	5	8
45	Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?. <i>Circulation</i> , 2016 , 134, 571-3	16.7	13
44	Improvement of skin wound healing in diabetic mice by kinin B2 receptor blockade. <i>Clinical Science</i> , 2016 , 130, 45-56	6.5	16
43	Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. <i>Diabetes Therapy</i> , 2016 , 7, 537-49	3.6	22
42	The evaluation of off-loading using a new removable oRTHOsis in DIABetic foot (ORTHODIAB) randomized controlled trial: study design and rationale. <i>Journal of Foot and Ankle Research</i> , 2016 , 9, 34	3.2	7
41	Beta-cell function is associated with carotid intima-media thickness independently of insulin resistance in healthy individuals. <i>Journal of Hypertension</i> , 2016 , 34, 685-91	1.9	8
40	Lifestyle intervention enhances high-density lipoprotein function among patients with metabolic syndrome only at normal low-density lipoprotein cholesterol plasma levels. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1172-81	4.9	12
39	Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2016 , 15, 5	8.7	15
38	Glutathione peroxidase-1 gene (GPX1) variants, oxidative stress and risk of kidney complications in people with type 1 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2016 , 65, 12-9	12.7	25
37	Gene Polymorphisms of FABP2, ADIPOQ and ANP and Risk of Hypertriglyceridemia and Metabolic Syndrome in Afro-Caribbeans. <i>PLoS ONE</i> , 2016 , 11, e0163421	3.7	5
36	Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: Amulticenter study. <i>International Journal of Cardiology</i> , 2016 , 220, 137-42	3.2	19
35	Dynamic Changes in Renal Function Are Associated With Major Cardiovascular Events in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 1259-66	14.6	26
34	Interaction between GPR120 p.R270H loss-of-function variant and dietary fat intake on incident type 2 diabetes risk in the D.E.S.I.R. study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 931-6	4.5	8
33	Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2432-9	5.6	52

32	Plasma Copeptin, Kidney Outcomes, Ischemic Heart Disease, and All-Cause Mortality in People With Long-standing Type 1 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 2288-2295	14.6	41
31	ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients. <i>Diabetologia</i> , 2016 , 59, 2321-2330	10.3	26
30	Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2015 , 14, 845	8.7	34
29	Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis. <i>European Heart Journal</i> , 2015 , 36, 2716-28	9.5	37
28	Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes. <i>Free Radical Biology and Medicine</i> , 2015 , 86, 16-24	7.8	12
27	ABCG8 polymorphisms and renal disease in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2015 , 64, 713-9	12.7	9
26	Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes. <i>Diabetes</i> , 2015 , 64, 3262-72	0.9	7
25	Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 309, F2-23	4.3	65
24	Antidepressant medication use and trajectories of fasting plasma glucose, glycated haemoglobin, β-cell function and insulin sensitivity: a 9-year longitudinal study of the D.E.S.I.R. cohort. <i>International Journal of Epidemiology</i> , 2015 , 44, 1927-40	7.8	13
23	Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Advances in Therapy</i> , 2015 , 32, 1029-64	4.1	23
22	Kinin receptor agonism restores hindlimb postischemic neovascularization capacity in diabetic mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 352, 218-26	4.7	17
21	Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015 , 17, 859-67	6.7	161
20	Contribution of the low-frequency, loss-of-function p.R270H mutation in FFAR4 (GPR120) to increased fasting plasma glucose levels. <i>Journal of Medical Genetics</i> , 2015 , 52, 595-8	5.8	22
19	Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study. <i>American Journal of Nephrology</i> , 2015 , 42, 107-14	4.6	28
18	Use of Fibrates Monotherapy in People with Diabetes and High Cardiovascular Risk in Primary Care: A French Nationwide Cohort Study Based on National Administrative Databases. <i>PLoS ONE</i> , 2015 , 10, e0137733	3.7	8
17	Defining the role of common variation in the genomic and biological architecture of adult human height. <i>Nature Genetics</i> , 2014 , 46, 1173-86	36.3	1339
16	Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 40-4	3.2	28
15	Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4656-63	5.6	87

14	Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort. <i>Diabetes Care</i> , 2014 , 37, 1425-31	14.6	48
13	Manganese superoxide dismutase (SOD2) polymorphisms, plasma advanced oxidation protein products (AOPP) concentration and risk of kidney complications in subjects with type 1 diabetes. <i>PLoS ONE</i> , 2014 , 9, e96916	3.7	23
12	Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes. <i>Diabetologia</i> , 2013 , 56, 2733-42	10.3	9
11	Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. <i>Diabetes Care</i> , 2013 , 36, 3639-45	14.6	59
10	FRI0546 Pituitary-adrenal function after prolonged glucocorticoid therapy in systemic disorders. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A559.3-A560	2.4	
9	Metformin use and mortality among patients with diabetes and atherothrombosis. <i>Archives of Internal Medicine</i> , 2010 , 170, 1892-9		252
8	Contrôle intensif de la glycémie: moins d'infarctus du myocarde. <i>Diabetologia Notes De Lecture</i> , 2010 , 2, 15-16		
7	Le salsalate, un dérivé de l'aspirine, pourrait être un anti-diabétique, en agissant plutôt sur l'insulinosécrétion que l'insulinosensibilité. <i>Diabetologia Notes De Lecture</i> , 2009 , 1, 1-2		1
6	Mesure de l'accumulation cutanée des produits avancés de la glycation: un progrès pour la prédiction du risque cardiovasculaire ?. <i>Diabetologia Notes De Lecture</i> , 2009 , 1, 31-32		
5	Le diabète et l'obésité: réellement des maladies héritées d'un passé de chasseurs-cueilleurs ?. <i>Diabetologia Notes De Lecture</i> , 2009 , 1, 35-36		1
4	La micro-angiopathie: plus de prévention possible après quelques années de diabète de type 2 ?. <i>Diabetologia Notes De Lecture</i> , 2009 , 1, 61-62		
3	Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabète de type 2, Néphropathie et Complications (DIACOMEDHUCOGENE) and Genetic Diabetes and type 2 Complications (SURDIAGENE) Studies. <i>Diabetes Care</i> , 2005 , 28, 125-30	14.6	58
2	Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. <i>Diabetes</i> , 2005 , 54, 2961-7	0.9	17
1	Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the Genesis France-Belgium Study. <i>Diabetes Care</i> , 2004 , 27, 2661-8	14.6	48